Global - Impulse Dynamics
  • Home
  • Patients
  • Providers
    • CE Mark Indications & Patient Selection
    • Procedure and Mode of Action
    • Publications
    • Instructions for Use and Product Manuals
  • Company
    • News
    • Ethics & Compliance
    • Resources
    • Clinical Trials
    • Careers
    • Contact Us
  • Events
  • Find A Doctor
  • REGION
    • US
    • DE
    • IT
    • Global
Select Page

The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China

by Impulse Dynamics | Dec 18, 2017 | Press Releases

NEWS The CFDA Approves Impulse Dynamics’ Optimizer System for Treatment of Chronic Heart Failure in China Orangeburg, New York & Stuttgart, Germany. December 18, 2017 – The China Food and Drug Administration (CFDA) has approved Impulse Dynamics’ Optimizer® system...

Recent Posts

  • Impulse Dynamics®’ INTEGRA-D Trial Completes Efficacy Phase
  • Impulse Dynamics Receives European CE Mark For Expanded Indication For Diastolic Heart Failure
  • Impulse Dynamics Expands Executive Leadership Team
  • Impulse Dynamics Surpasses 10,000 Patients Benefiting from CCM® Therapy for Heart Failure
  • Impulse Dynamics Completes $136M Financing Round

Recent Comments

    Archives

    • June 2025
    • November 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • January 2022
    • February 2021
    • January 2021
    • April 2020
    • March 2020
    • December 2019
    • November 2019
    • October 2019
    • August 2019
    • March 2019
    • May 2018
    • December 2017
    • August 2017
    • May 2017
    • March 2017
    • September 2016
    • May 2016
    • March 2016
    • January 2016
    • November 2015
    • August 2015
    • July 2015
    • January 2015
    • December 2014

    Categories

    • News and Events
    • Press Releases

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Like most websites on the internet, this website uses cookies. By using our website, you agree to our Cookie Policy. I Accept